VOLUME - 15, ISSUE - 03, MARCH - 2026 • PRINT ISSN No. 2277 - 8160 • DOI : 10.36106/gjra

Original Research Paper

Ayurveda

DIETARY FACTORS AS COMMON GROUND: ĀHĀRAJA NIDĀNA OF JALODARA AND MODERN RISK FACTORS OF LIVER CIRRHOSIS

Dr. Haripriya Panjabi* M.D. (Ayu.) | Department of Kriya Sharira*Corresponding Author

Dr. Manish Patel Head of Department, Kayachikitsa

Dr. Kalapi Patel Principal and Superintendent | Head of Department, Panchakarma

ABSTRACT

Background: Liver disease driven by dietary imbalance has been recognized across medical traditions for centuries, yet the systematic convergence between classical Ayurvedic etiological thinking and contemporary hepatological evidence has rarely been examined in depth. Jalodara, the Ayurvedic designation for pathological intra-abdominal fluid accumulation, is described in the Brihat Trayi texts as a condition with a pronounced dietary origin. The category of Āhāraja Nidāna (food-related causative factors) occupies a central position within the Nidāna Panchaka of Jalodara as elaborated in the Charaka Samhita, Sushruta Samhita, and Ashtanga Hridayam. Contemporary hepatology identifies a remarkably similar constellation of dietary risk factors, including chronic alcohol use, saturated fat excess, dietary fructose, and caloric overconsumption, as the dominant modifiable contributors to liver cirrhosis and its commonest complication, ascites. **Objectives:** This study aimed to compile and analyze the Āhāraja Nidāna of Jalodara from primary classical sources; to correlate each dietary causative factor with evidence-based modern risk factors for hepatic steatosis, progressive fibrosis, and cirrhotic ascites; to trace the shared pathogenic sequence from dietary insult to hepatic decompensation across both frameworks; and to draw implications for integrative dietary management. **Materials and Methods:** Charaka Samhita (Chikitsa Sthana 13), Sushruta Samhita (Nidana Sthana 7), Ashtanga Hridayam (Nidana Sthana 12), Ashtanga Sangraha, and Madhava Nidana were reviewed in the original Sanskrit with standard commentaries. Peer-reviewed literature including systematic reviews, meta-analyses, and dietary guidelines for liver disease was retrieved from PubMed, Scopus, and the Cochrane Database.**Results:** Ten principal Āhāraja Nidāna categories demonstrate direct conceptual and mechanistic parallels with modern hepatological dietary risk factors. Guru Ahāra parallels saturated fat-induced steatosis; Madyapāna maps onto ethanol hepatotoxicity; Ati Madhura Ahāra corresponds to fructose-driven de novo lipogenesis; Abhishyandi Ahāra parallels refined carbohydrate-mediated steatosis; and Viruddha Ahāra aligns with dietary-pattern-induced gut barrier disruption. The Samprapti of Jalodara, proceeding from Mandāgni through Āma, Srotorodha, and Yakrit Vriddhi to peritoneal fluid accumulation, mirrors the NAFLD-to-cirrhosis-to-ascites continuum with notable mechanistic consistency. **Conclusion:** The Āhāraja Nidāna of Jalodara constitutes a clinically relevant, evidence-congruent dietary risk classification that predates modern hepatological understanding by approximately two millennia. Integrating this classical framework with contemporary nutritional hepatology offers both preventive and therapeutic dietary strategies grounded in traditional knowledge and supported by current science.

KEYWORDS : Jalodara; Āhāraja Nidāna; Liver Cirrhosis; Ascites; NAFLD; Dietary Risk Factors; Mandāgni; Āma; Samprapti; Integrative Hepatology; Ayurvedic Dietetics

1. INTRODUCTION

Liver cirrhosis stands as one of the most consequential chronic diseases worldwide, with the World Health Organization [19] estimating that it claims more than one million lives annually. The majority of this mortality is attributable to modifiable risk factors, principally alcohol use, obesity-driven non-alcoholic fatty liver disease (NAFLD), and chronic viral hepatitis. Ascites, the most frequent complication of cirrhosis, develops in roughly half of all patients within a decade of diagnosis and is associated with a two-year survival rate below 50%, underscoring the critical importance of early risk modification.

Within the classical Ayurvedic medical tradition, *Jalodara* occupies an analogous clinical position. Described as a sub-type of *Udararoga* (disorders of the abdominal cavity), it is characterized in the *Charaka Samhita Chikitsa Sthana* (13th chapter) as the accumulation of *Jala* (watery fluid) within the *Udara*, arising from the interplay of *Tridosha* vitiation, *Agni* impairment, and *Yakrit* (liver) dysfunction [1]. What makes the classical account particularly compelling is the sustained attention it devotes to *Āhāraja Nidāna*, the dietary causative factors, enumerating specific food categories, eating behaviors, and dietary incompatibilities that collectively compromise hepatic integrity.

Despite the obvious conceptual overlap between this classical dietary etiological framework and modern nutritional hepatology, no prior study has subjected it to a systematic, text-critical, and evidence-based comparative analysis. The present article undertakes that task. Drawing on primary Sanskrit texts annotated by their standard commentators, namely *Chakrapanidatta* on *Charaka*, *Dalhana* on *Sushruta*, and *Arunadatta* and *Hemadri* on *Vagbhata*, together with contemporary hepatological literature, it aims to produce a rigorous interdisciplinary synthesis.

The study's rationale rests on three practical grounds. Dietary change is the most accessible and cost-effective intervention available across the liver disease spectrum, from prevention through active management. Ayurvedic dietary science, grounded in an individualized understanding of *Prakriti*, *Agni*, and *Srotas* physiology, offers nuanced prescriptions that could usefully complement existing clinical nutritional guidelines. Finally, the close structural parallel between classical *Samprapti* and modern pathogenesis offers a theoretical scaffold on which integrative clinical protocols can be rationally built.

2. Jalodara: Classical Definition, Classification, and *Nidāna*

2.1 Definition and Classification

Charaka defines *Jalodara* in *Chikitsa Sthana* (13/17) as the condition in which *Jala* accumulates within the *Udara* following *Agni Dushti* and *Dosha* vitiation originating in the *Kostha* (gastrointestinal tract) and spreading to involve the *Yakrit* and *Pleeha* [1]. *Sushruta* (*Nidana Sthana* 7/5–9) enumerates eight varieties of *Udararoga*, including *Vatodara*, *Pittodara*, *Kaphaja Udara*, *Sannipataja Udara*, *Plihodara*, *Baddhagudodara*, *Chidrodara*, and *Jalodara*, of which *Jalodara* is the most clinically grave and the most closely associated with *Yakrit* involvement [2].

Ashtanga Hridayam (*Nidana Sthana* 12/1-5) consolidates this classification and highlights the central role of *Mandāgni* in all forms of *Udararoga*, noting that *Jalodara* specifically arises when *Mandāgni*-generated *Āma* obstructs the *Rasavaha* and *Udakavaha Srotas*, causing peritoneal fluid accumulation [3]. This classical description maps remarkably well onto the modern understanding of cirrhotic ascites as a consequence of portal hypertension, hypoalbuminaemia, and renal sodium-water retention, all downstream effects of progressive hepatic synthetic and architectural failure [6].

2.2 Nidāna Panchaka of Jalodara

Classical Ayurvedic diagnosis is structured around the *Nidāna Panchaka* framework: *Nidāna* (causative factors), *Pūrvarūpa* (prodromal features), *Rūpa* (clinical manifestations), *Upashaya* (therapeutic test), and *Samprapti* (pathogenesis). Within *Nidāna*, the texts distinguish *Āhāraja* (dietary), *Vihāraja* (behavioral), *Mānasika* (psychological), and *Anya* (miscellaneous) causative categories. *Āhāraja Nidāna* receives prominent treatment across all three *Brihat Trayi* texts, a priority that reflects the foundational Ayurvedic maxim that food is simultaneously the greatest medicine and the principal cause of disease (*Charaka Samhita*, *Sutra Sthana* 25/40).

Madhava Nidana (*Udararoga Nidana*, Chapter 24) elaborates additional dietary factors and explicates their mechanism of action through *Agni Dushti*, *Āma* formation, and *Srotas* obstruction, furnishing the pathophysiological substructure that underlies the comparative analysis presented here [5].



Figure 1. Samprapti of Jalodara and Parallel Pathogenesis in Modern Hepatology-a comparative flow diagram tracing conceptual correspondence from Nidāna Sevana (dietary insult) to Jalodara (cirrhotic ascites).

Table 1. Nidāna Pañcaka of Udararoga: Comparative Analysis Across Classical Texts

Nidāna Category	Charaka Samhitā (Chi. 13)	Sushruta Samhitā (Ni. 7)	Ashtānga Hridayam (Ni.12)	Ashtānga Sangraha (Ni.12)
Āhāraja Nidāna				
Ati-Ushna (very hot food)	+	–	–	–
Lavana (excess salt)	+	–	–	–
Kshara (alkaline/caustic foods)	+	–	–	–
Vidāhī (pungent/irritant foods)	+	–	–	–
Amla (excess sour taste)	+	–	–	–
Gara Visha (ingested food toxins)	+	–	–	–
Rūksha (excessively dry foods)	+	+	–	–
Viruddha (incompatible foods)	+	–	–	–
Ashuchi Bhojana (impure food)	+	+	+	+
Vihāraja Nidāna				
Vegadhārana (suppression of urges)	+	–	–	–
Mālasanchaya (fecal accumulation)	–	+	+	+
Mithyā Samsarjana (improper post-illness diet)	+	–	–	–
Sneha Mithyācharana (misuse of oleation)	–	+	–	–
Rogaja Nidāna				
Plīhā Roga (splenic disorder)	+	–	–	–
Arsha Roga (haemorrhoids)	+	–	–	–
Grahanī Roga (malabsorption)	+	–	–	–
Mandāgni (diminished digestive fire)	+	–	–	–
Āma (undigested toxic metabolite)	+	–	–	–

Note. Sources: [1,2,3,4]. + = mentioned; – = not mentioned.

3. Liver Cirrhosis and Dietary Risk Factors: A Modern Perspective

3.1 Epidemiology and Etiology

Liver cirrhosis represents the histological end-point of any chronic hepatic injury that overwhelms the liver's regenerative capacity. Three etiologies dominate globally: alcoholic liver disease (ALD), accounting for approximately 30–40% of cirrhosis-related mortality in high-income countries; NAFLD and non-alcoholic steatohepatitis (NASH), now the fastest-growing indication for liver transplantation worldwide; and chronic viral hepatitis B and C [11]. In India, ALD and NAFLD together carry the greatest cirrhosis burden, with NAFLD prevalence estimated at 9-32% in the general population and substantially higher in urban communities [12].

Dietary factors are causally implicated across all three etiological pathways. Alcohol is the proximate cause of ALD. Excessive caloric intake, the composition of dietary fat, high fructose consumption, and gut microbiome-disrupting dietary patterns are the principal modifiable drivers of NAFLD. Even in viral hepatitis, dietary choices modulate the pace of fibrosis progression, as high-fat diets, alcohol use, and obesity independently accelerate fibrogenesis [16].

3.2 Pathogenic Mechanisms Linking Diet to Cirrhosis

Three diet-to-liver pathogenic axes have been well characterized. Through the gut-liver axis, dietary patterns that promote intestinal dysbiosis, particularly those high in fat and refined sugar and low in fiber, increase intestinal epithelial permeability. This allows bacterial lipopolysaccharide (LPS) to enter the portal circulation and activate hepatic Kupffer cells via TLR4 signalling, releasing pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β [10]. Through the lipid-fibrosis axis, excess dietary lipids, particularly saturated and trans-fatty acids, induce hepatocyte lipotoxicity, endoplasmic reticulum stress, and mitochondrial dysfunction; they also activate hepatic stellate cells via TGF-β1 paracrine signalling, initiating the fibrogenic cascade [16]. Through the fructose-lipogenesis axis, dietary fructose, metabolized almost exclusively in the liver, drives de novo lipogenesis through SREBP-1c and ChREBP transcription factors, generating the hepatic lipid overload that initiates and sustains NAFLD [11].

4. *Āhāraja Nidāna* of Jalodara and Modern Dietary Risk Factors: Comparative Analysis

Table 2 presents a systematic correlation of ten principal Āhāraja Nidāna categories enumerated across the Brihat Trayi with their modern dietary risk factor counterparts. Classical food examples are drawn directly from the original textual sources; the modern correlations are grounded in evidence-based hepatological literature.

Table 2. *Āhāraja Nidāna* of Jalodara and Modern Dietary Risk Factor Correlations

Āhāraja Nidāna (Ayurvedic)	Classical Food Examples (Dravya)	Modern Dietary Risk Factor Correlation
Guru Ahāra *(Heavy, hard-to-digest foods)*	*Māsha* (black gram), *Nishpāva* (flat beans), *Pishtāhāra* (flour preparations), *Dadhi* in excess, *Mahisha Māmsa* (buffalo meat)	Dietary saturated fatty acids, ultra-processed foods, and red or processed meats promote hepatic de novo lipogenesis, insulin resistance, and progressive steatosis [6,7]
Abhishyandi Ahāra *(Channel-obstructing foods)*	*Dadhi*, excess *Dugdha Vikāra*, *Navānna* (freshly harvested grain), *Guda* (jaggery in excess)	High-fructose corn syrup and refined carbohydrates impair hepatic sinusoidal flow, elevate serum triglycerides, and accelerate NAFLD progression [16]
Sheeta / Paryushita Ahāra *(Cold, stale foods)*	*Paryushita* (stale food), chilled beverages, *Hima Jala* (iced water)	Cold processed foods impair digestive enzyme activity and reduce hepatic Phase I/II detoxification efficiency [18]
Ati Madhura Sevana *(Excessive sweet taste)*	*Ikshurasa* (sugarcane juice in excess), *Guda*, *Khanda*, *Pāyasa*, *Modaka*	Dietary fructose and sucrose stimulate SREBP-1c, drive de novo lipogenesis, and promote NAFLD-to-NASH transition with early fibrosis [11,10]
Ati Amla Sevana *(Excessive sour taste)*	Excess *Dadhi*, *Āranāla* (fermented liquids), *Sukta* (vinegar-like preparations), *Kānji*	Excess fermented and acidic foods promote intestinal dysbiosis, raise portal LPS load, and activate hepatic Kupffer cells via TLR4 signalling [10]

Āhāraja Nidāna (Ayurvedic)	Classical Food Examples (Dravya)	Modern Dietary Risk Factor Correlation
Ati Lavana Sevana *(Excessive salty taste)*	Excess *Saindhava*, pickled preparations, heavily salted food	High dietary sodium promotes ascitic fluid retention via RAAS activation and independently enhances hepatic stellate cell fibrogenesis [6]
Madyapāna *(Alcohol consumption)*	*Surā* (fermented grain liquor), *Āsava-Arishtā* in excess, all *Madya* varieties	Ethanol is a direct hepatotoxin; it induces CYP2E1-mediated reactive oxygen species, forms acetaldehyde–protein adducts, and causes mitochondrial dysfunction leading to alcoholic cirrhosis [8]
Viruddha Ahāra *(Incompatible food combinations)*	*Matsya* + *Dadhi*; *Ksheera* + *Amla dravya*; *Madya* + *Ksheera*; *Ushna* + *Sheeta* together	Incompatible food pairings generate advanced glycation end-products (AGEs), promote intestinal hyperpermeability, and heighten systemic inflammatory burden with hepatocellular consequences [17]
Ajeerna Bhojana *(Eating before prior meal digests)*	Repeated meals before complete *Avasthāpāka* of prior intake; irregular meal timing	Disruption of circadian eating patterns impairs hepatic clock gene expression (BMAL1, CLOCK) and promotes metabolic liver disease progression [16]
Atimātra Bhojana *(Excessive food quantity)*	Overconsumption of *Guru*, *Snigdha*, and *Madhura Dravyas* beyond digestive capacity	Caloric excess drives hepatic lipid overload, adipose tissue dysfunction, and ectopic fat deposition; it is the principal epidemiological driver of NAFLD globally [12]

Note. Sources: [1,2,3,5,6,7,16,11,12,8,10].

5. *Samprapti of Jalodara* and Modern Hepatic Disease Progression: A Parallel Framework

The Samprapti of Jalodara described in the classical texts follows a coherent sequential logic: Āhāraja Nidāna Sevana → Mandāgni → Āma Utpatti → Rasavaha Srotas Dushti → Yakrit involvement → Srotorodha → Yakrit Daurbalya → Jalodara. This classical sequence maps with considerable fidelity onto the modern NAFLD-to-cirrhosis-to-ascites continuum, as detailed in Table 3.

Table 3. *Samprapti of Jalodara* and Modern Hepatic Disease Progression: A Parallel Framework

Ayurvedic Samprapti Stage	Classical Interpretation	Modern Hepatological Parallel
Āhāraja Nidāna Sevana	Sustained exposure to the dietary causative factors	Consumption of hepatotoxic or steatogenic dietary agents over time
Mandāgni *(Jathārāgni Daurbalya)*	Diminished digestive fire; impaired *Avasthāpāka* at gastric and tissue levels	Diet-induced intestinal dysbiosis; increased gut epithelial permeability; portal influx of LPS and bacterial metabolites
Āma Utpatti	Formation of toxic, incompletely metabolized residues within the *Kostha*	Hepatic lipotoxicity; accumulation of advanced glycation end-products; mitochondrial reactive oxygen species (ROS)
Rasavaha Srotas Dushti	Contamination and impaired function of the nutritive plasma transport channels	Chylomicron and VLDL overload; hypertriglyceridaemia; excess lipid entry into portal circulation
Yakrit Sanga / Yakrit Vriddhi	Hepatic channel obstruction and parenchymal engorgement	Hepatic steatosis (NAFLD); Kupffer cell activation; hepatocyte lipid overload with oxidative stress
Rakta Dushti / Pitta Dushti	Vitiation of blood-borne and Pitta-mediated metabolic pathways	Hepatocellular inflammation (NASH); elevated serum transaminases; oxidative hepatocellular injury
Srotorodha *(progressive)*	Progressive obstruction of *Srotas* by accumulated *Āma*	Hepatic fibrogenesis; sinusoidal collagenization; portal hypertension via stellate cell activation
Yakrit Daurbalya *(Karma Kshaya)*	Hepatic functional insufficiency reflecting synthetic failure	Decompensated cirrhosis; coagulopathy; hypoalbuminaemia; hepatic encephalopathy
Jalodara Vyakti *(Udarābhishyanda)*	Full clinical manifestation of Jalodara with peritoneal fluid accumulation	Ascites (SAAG > 1.1 g/dL); risk of spontaneous bacterial peritonitis; hepatorenal syndrome; end-stage liver disease

Note. Classical stages derived from [1,3,5]. Modern correlates per [6,7].

5.1 *Mandāgni* as the Pivotal Common Mechanism

Both traditions converge on an analogous functional impairment as the central pivot through which diet translates into hepatic disease. Classically, this is Mandāgni; in modern hepatology, it corresponds to impaired intestinal barrier function and hepatic metabolic dysregulation. Charaka's declaration (Sutra Sthana 28/6) that all disease originates from impaired Agni finds a contemporary echo in the recognition that gut-liver axis dysregulation, initiated by diet-induced dysbiosis and intestinal hyperpermeability, underpins the pathogenesis of NAFLD, ALD, and progressive hepatic fibrosis alike [9,10].

5.2 *Āma* and Lipotoxicity: The Intermediate Toxic Mediator

Āma, the classical designation for incompletely transformed, toxic metabolic residue produced under conditions of Mandāgni, corresponds functionally to the cluster of lipotoxic mediators identified in modern hepatopathology: free fatty acids (particularly palmitate and stearate), diacylglycerols, ceramides, lysophosphatidylcholine, and reactive oxygen species. These agents share the properties classically ascribed to Āma, being Picchila (sticky), Guru (heavy), Abhishyandi (channel-obstructing), and pro-inflammatory. They induce organellar stress, membrane disruption, and paracrine activation of inflammatory and fibrogenic cells within the hepatic microenvironment [16].

Table 4. *Nidāna Panchaka* of *Jalodara:* Correlation with the Modern Hepatological Framework

Component	Sanskrit Term	Classical Definition	Application in Jalodara	Modern Hepatological Correlate
1. *Nidāna*	*Hetu / Kārana*	Causative factors initiating the pathological process; classified as Āhāraja, Vihāraja, and Mānasika	*Guru*, *Rūksha*, *Vidāhī*, *Amla*, *Lavana Ahāra*; *Madyapāna*; *Viruddha Ahāra*; *Mandāgni*-promoting dietary habits	Dietary risk factors: alcohol (ALD), high-fat/fructose diet (NAFLD/NASH), viral hepatitis co-factors; all are modifiable etiological determinants
2. *Pūrvarūpa*	*Prodromata*	Premonitory symptoms preceding full disease manifestation; reflect dosha accumulation within srotas	*Kshudhānāsha*, *Pāda Shopha*, *Bhukte Vidadhyāt*, *Bastisandhi Ruja*, *Rāji Janma* on Udara	Subclinical hepatic dysfunction: anorexia, ankle oedema, postprandial discomfort, early abdominal distension; detectable on liver function tests before clinical ascites
3. *Rūpa*	*Vyakta Lakshana*	Fully manifested signs and symptoms of established disease; the basis of classical diagnosis	*Adhmāna*, *Mandāgni*, *Pāda Shopha*, *Sādana*, *Mālasanga*, *Dāha*, *Trishna*, *Kārshya*	Decompensated cirrhosis: abdominal distension, hepatic encephalopathy, peripheral oedema, fatigue, constipation, jaundice, sarcopenia
4. *Upashaya*	*Sātmya Parikshā*	Therapeutic test: factors that relieve symptoms confirm the responsible dosha and validate diagnosis	*Laghu-Dīpana Ahāra* relieves *Mandāgni*; *Tikta-Kāshāya Rasa* reduces *Kapha-Āma*; *Virechana* improves *Udara* distension	Alcohol abstinence reduces ALD progression; low-sodium diet with diuretics (spironolactone) resolves ascites; TIPS procedure for refractory ascites

Component	Sanskrit Term	Classical Definition	Application in Jalodara	Modern Hepatological Correlate
5. *Samprapti*	*Rogotpatti Krama*	Complete pathogenesis: sequence of dosha vitiation, dhātu involvement, srotas obstruction, and disease manifestation	*Mandāgni* → *Āma* → *Rasavaha/Udakavaha Srotorodha* → *Yakrit Vriddhi* → Jala accumulation in *Udara*	Dietary insult → Hepatic steatosis/NASH → Gut dysbiosis/LPS portal endotoxaemia → Portal hypertension + hypoalbuminaemia → Hepatic fibrosis → Cirrhotic ascites

Note. Classical framework - [1,2,3,5]. Modern correlates —-[6,7].

5.3 *Srotorodha* and *Progressive Hepatic Fibrosis*

Srotorodha, the progressive obstruction of biological channels (*Srotas*) by accumulated Ā*ma*, maps most precisely onto the process of hepatic fibrosis in modern pathology. Sinusoidal capillarization during early fibrosis, characterized by loss of LSEC fenestrations and collagen deposition in the Space of Disse, represents a structural correlate of *Srotomukha Avarodha* (channel orifice blockage impairing bidirectional nutrient exchange). Progressive portal fibrosis culminating in portal hypertension corresponds to obstruction of *Raktavaha Srotas*. The final stage, *Yakrit Daurbalya* manifesting as ascites, precisely mirrors the hypoalbuminaemia-driven, portal-hypertension-mediated fluid redistribution that constitutes cirrhotic ascites [6].

6. Integrative Dietary Guidelines: Classical Wisdom and Modern Evidence

6.1 Foods to Avoid: Convergent Recommendations

The Ayurvedic dietary prohibition on *Guru*, *Abhishyandi*, *Madya*, *Ati Madhura*, *Ati Lavana*, *Viruddha*, and *Paryushita Ahāra* in *Jalodara* management corresponds closely to contemporary clinical dietary guidance for patients with cirrhosis. Modern recommendations include complete alcohol abstinence, which is the single most impactful dietary intervention in ALD and a critical modifying factor across all cirrhosis etiologies; restriction of saturated and trans-fats; elimination of high-fructose corn syrup and added sugars; dietary sodium restriction to below 2000 mg/day in patients with ascites; and avoidance of raw or incompletely cooked foods that risk bacterial contamination in immunocompromised cirrhotic patients [6,7].

6.2 Foods to Favor: Classical Pathya in a Modern Context

Charaka's *Pathya* (wholesome dietary recommendations) for *Jalodara* include *Lāja* (puffed grain), *Yava* (barley), *Mudga* (green gram), *Tākra* (buttermilk), *Purāna Shāli* (aged rice), *Saindhava Lavana* in moderation, and *Tikta Rasa* (bitter-tasting) foods. Each finds modern validation as a hepatoprotective, anti-fibrotic, or microbiome-supportive dietary element [13,14]. *Yava* (barley) is rich in beta-glucan, a prebiotic fiber with demonstrated capacity to reduce hepatic steatosis. *Mudga* supplies readily digestible plant protein that is particularly important for preventing the sarcopenia that accompanies cirrhosis. *Tākra* contributes probiotic microorganisms capable of modulating gut-liver axis dysbiosis. *Tikta Rasa* foods such as *Nimba* (neem), *Guduchi*, and *Patola* contain phytochemicals with hepatoprotective properties under active investigation [15].

6.3 Meal Timing, Quantity, and Pattern

The classical prohibitions on *Ajeerna Bhojana* (eating before the prior meal has been fully processed) and *Atimātra Bhojana* (eating beyond satiety) address dimensions of dietary behavior now recognized as hepatologically significant. Circadian biology research has shown that restricting food intake to an 8-10 hour daily window, broadly consistent with the classical injunction to eat only after complete *Avasthāpāka* of the previous meal, significantly reduces hepatic steatosis and improves metabolic parameters in patients with NAFLD [16]. Caloric restriction, corresponding to the Ayurvedic principle of *Mātravat Āhāra*, remains the most universally validated lifestyle intervention for NAFLD; a sustained 7–10% reduction in body weight produces histological improvement, including NASH resolution and fibrosis regression [7].

7. DISCUSSION

The analysis presented here shows that the Ā*hāraja Nidāna* of *Jalodara* constitutes a comprehensive, mechanistically coherent dietary risk classification that anticipates the principal dietary contributors to liver cirrhosis identified by modern hepatology. This is not a superficial or coincidental resemblance. It reflects the empirical acuity of classical Ayurvedic physicians who, through sustained clinical observation across generations, isolated the same dietary patterns, heavy, fatty, sweet, salty, alcoholic, incompatible, excessive, and irregularly timed foods, as the primary promoters of progressive hepatic disease.

Several correspondences are of particular clinical significance. The prohibition on *Madyapāna* is the most directly validated: ethanol hepatotoxicity is now understood at the molecular level in a manner that fully corroborates *Charaka*'s categorical identification of alcohol as the most potent Ā*hāraja Nidāna* for *Yakrit*-related disorders [8]. The proscription on *Ati Madhura Ahāra* is similarly prescient in the context of the modern fructose hypothesis of NAFLD. The discovery that dietary fructose, unlike glucose, is exclusively hepatically metabolized and uniquely potent in driving de novo lipogenesis ranks among the most important insights of nutritional hepatology, yet Ayurvedic texts identified excess sweet foods as hepatotoxic two thousand years earlier [11].

The *Viruddha Ahāra* concept poses the greatest translational challenge, as contemporary food science lacks a systematic framework equivalent to the classical theory of dietary incompatibility. Nonetheless, emerging research on dietary pattern interactions, the formation of advanced glycation end-products from specific food combinations under thermal processing, and the complex effects of combined dietary components on the gut microbiome suggests that this classical concept captures real biological phenomena that are only beginning to yield to mechanistic investigation [17].

A key limitation of this study is the profound methodological difference between the epistemic traditions within which classical and modern dietary knowledge were generated. Ā*hāraja Nidāna* was established through clinical observation, conceptual analysis, and inferential reasoning within the Ayurvedic tradition, which does not clearly separate food as pharmacological agent from food as social or cultural practice. Modern dietary risk factor research depends on epidemiological methods, cohort studies, meta-analyses, and randomized controlled trials, each carrying distinct methodological constraints. Claims of correspondence across these methodological divides must therefore be advanced with appropriate qualification.

Despite this limitation, the clinical implications are considerable. The *Pathya-Apathya* guidelines for *Jalodara* offer a culturally embedded and linguistically accessible dietary counseling framework for Indian patients with liver disease, for whom Western-derived dietary guidelines may carry limited practical relevance. From a research perspective, the comparative framework generates testable hypotheses: whether adherence to classical *Jalodara Apathya* predicts lower incidence of NAFLD in prospective Indian cohort studies, and whether *Pathya* dietary patterns demonstrate measurable hepatoprotective effects in rigorously designed clinical trials.

8. CONCLUSION

The Ā*hāraja Nidāna* of *Jalodara*, as elaborated across the *Brihat Trayi* and *Madhava Nidana*, constitutes a comprehensive dietary risk framework that demonstrates remarkable conceptual congruence with the modern evidence base for dietary risk factors in liver cirrhosis. Across ten major dietary categories, heavy foods, channel-obstructing foods, cold and stale foods, excess sweet, sour, and salty tastes, alcohol, incompatible combinations, irregular meal timing, and caloric excess, classical Ayurvedic dietary pathology maps with consistent mechanistic fidelity onto contemporary hepatological understanding of steatosis, inflammation, fibrosis, and ascites.

The shared pathogenic narrative, expressed classically as *Mandāgni*, Ā*ma*, *Srotorodha*, and *Jalodara*, and in modern terms as gut dysbiosis, lipotoxicity, hepatic fibrosis, and cirrhotic ascites, represents one of the most compelling instances of cross-traditional medical convergence in the integrative medicine literature. The dietary risk framework encoded within Ayurvedic Ā*hāraja Nidāna* deserves not merely historical recognition but active clinical investigation. Its systematic evaluation within the framework of evidence-based nutritional hepatology could yield practical benefits for liver disease prevention and management in Indian healthcare settings.

Declaration

Conflict of Interest: The authors declare no conflict of interest.

Funding: This study received no external funding.

Authors' Contributions: Dr. Haripriya Panjabi - concept development, classical text analysis, and manuscript writing. Dr. Manish Patel - clinical correlation, *Kayachikitsa* framework, review and editing. Dr. Kalapi Patel - institutional supervision, critical review, and final approval.

Ethical Statement: This is a conceptual and review article. No human subjects or animal experimentation was involved. All classical references are drawn from publicly available published editions.

REFERENCES

1. Agnivesha. Charaka Samhita, revised by Charaka and Dridhabala. Acharya YT, editor. 5th ed. Varanasi: Chaukhamba Sanskrit Sansthan; 2001. (Sutra Sthana 25/40; Chikitsa Sthana 13/17, 13/25-40).
2. Sushruta. Sushruta Samhita. Acharya YT, editor. Varanasi: Chaukhamba Sanskrit Sansthan; 2002. (Nidana Sthana 7/5-9, 7/14-22).
3. Vagbhata. Ashtanga Hridayam: With Sarvangasundara commentary of Arunadatta and Ayurvedarasayana of Hemadri. Paradkar Vaidya BH, editor. Varanasi: Krishnadas Academy; 2000. (Nidana Sthana 12/1-15).
4. Vagbhata. Ashtanga Sangraha. Sharma S, editor. Varanasi: Chaukhamba Sanskrit Series; 2006. (Nidana Sthana 12).
5. Madhavakara. Madhava Nidanam (Rogavinischaya): With Madhukosha commentary. Varanasi: Chaukhamba Sanskrit Sansthan; 2004. (Udararoga Nidana, Chapter 24).
6. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406-60.
7. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57.
8. Seitz HK, Bataller R, Cortez-Pinto H, Gao B, Gual A, Lackner C, et al. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4(1):16.
9. Singh RH. Exploration of the role of Agni in the management of metabolic syndrome. Ayu. 2011;32(4):447-52.
10. Tilg H, Moschen AR. Evolution of inflammation in non-alcoholic fatty liver disease: The multiple parallel hits concept. Hepatology. 2010;52(5):1836-46.
11. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686-90.
12. Mueller M, Mohan SK, Agrawal A. NAFLD, obesity and metabolic syndrome: Mechanisms and common pathways. Liver Int. 2021;41(S1):1-11.
13. Sharma PV. Dravyaguna Vijnana. Vols. 1-2. Varanasi: Chaukhamba Bharati Academy; 1999.
14. Sharma H, Chandola HM, Singh G, Basisht G. Utilization of Ayurvedic herbs in metabolic syndrome management. Evid Based Complement Alternat Med. 2012;2012:897735.
15. Mistry N, Krupanidhi S. Hepatoprotective herbs in Ayurveda and their correlation with modern hepatology. J Ayurveda Integr Med. 2019;10(2):121-8.
16. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908-22.
17. Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014;99(3):535-42.
18. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M. ESPEN guidelines for nutrition screening 2002. Clin Nutr. 2003;22(4):415-21.
19. World Health Organization. Global status report on alcohol and health 2018. Geneva: WHO Press; 2018.
20. Poupon R. Ursodeoxycholic acid and bile-acid therapies in liver diseases. Gastroenterology. 2012;143(6):1451-3.